TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04050683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study - Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Description: Prior to and 1-3 days after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). Subjects with abnormal heart pressures during TIPS will have a right heart catheterization (RHC) to monitor heart function, blood flow, and pressures in and around the heart. The subject will be admitted to the Cardiovascular Intensive Care Unit and have a TTE all of which are standard of care. Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; TTEs; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes. Diagnostic RHC will be done as needed per standard of care.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control - Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Description: Subject's with normal heart pressures who are having elective (planned in advance and not due to an emergency) TIPS due to refractory ascites (fluid build up in the belly that does not go away or comes back shortly after being removed). Prior to and 1-3 days after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). The subject will be admitted to the hospital after TIPS for standard of care monitoring.~Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes.
Study: NCT01572506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biotin RBC survival

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biotin RBC survival

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biotin RBC survival

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biotin RBC survival
Study: NCT02638948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986142
Description: BMS986142 specific dose on specific days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986142
Description: BMS986142 specific dose on specific days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of BMS-986142 specific dose on specific days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate specific dose on specific days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate specific dose on specific days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate specific dose on specific days
Study: NCT02901015

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assessment battery A
Description: Social cognition tests version A are administered to the patients

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assessment battery B
Description: Social cognition tests version B are administered to the patients
Study: NCT03863340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interruptions of work tasks
Description: During each activity two interruptions/breaks were selected randomly from a set of ten predetermined actions:~Active break types:~* Move shoulder and upper back~* Swing arms near the body~* Three slow but forceful elevations of the shoulders, a relaxation exercise based on the principles developed by Jacobson~* Stand up and stretch~* Slowly turn head in all possible directions.~Passive break types:~* Tell a couple of jokes~* Stand up and have a drink~* Relaxing the trapezius~* Questions on actual posture and feelings of comfort / discomfort.~* A short rest on the couch
Study: NCT00797654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information-motivation-behavior skills and cognitive processing therapy
Description: Treatment will include elements from effective interventions for reducing risky sexual behaviors and reducing post-traumatic stress disorder (PTSD) symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre and Post HIV-Test Counseling
Description: Treatments are aimed at assessing and reducing behaviors that put participants at high risk of HIV infection.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre and Post HIV-Test Counseling
Description: Treatments are aimed at assessing and reducing behaviors that put participants at high risk of HIV infection.
Study: NCT03265600

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Training for Primary Care
Description: MTPC is a referral-based, insurance-reimbursable 8-week program that can be delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours long for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action planning protocol during Week 7.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 60-minute Introduction to Mindfulness
Description: Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, discussion, and an orientation to an 8-week mindfulness group. They are also given a list of leading community, online, print, and smartphone mindfulness resources.
Study: NCT04822038

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 5000 UI Vitamin D3 daily by 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary recommendations
Description: Dietary recommendations based on food rich in 25 (OH) vitamin D
Study: NCT00036569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa
Description: 0.3 mg/kg subcutaneously once a week for 4 weeks beginning 2-10 weeks after completion of radiation therapy and continued until disease progression or one of the other off study criteria.
Study: NCT03276351

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-Stemmed with Hybrid Fixation
Description: Long-stemmed revision implant with hybrid fixation for total knee arthroplasty

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short-Stemmed with Augmented Fixation
Description: Short-stemmed primary implant with augmented fixation for total knee arthroplasty
Study: NCT04984148

Intervention type: DIAGNOSTIC_TEST
Intervention: CT
Description: Contrast-enhanced thoracic computed tomography
Study: NCT04936152

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mime therapy using tablet PC mirror application
Description: After the baseline assessment, The patient in the experimental group will receive mirror therapy and mime therapy.~Exercises time period is 30 min/session~Mime Therapy Using Tablet PC:~Mirror therapy using tablet PC mirror application We will use a tablet PC mirror application that can convert images from right to left. In the mirror group, the mirror application was used during the exercise. Patients watched the tablet PC screen. The mirror application converts the image from right to left.~• Mime therapy include Mime therapy will consists of auto massage- effleurage and kneading for 10 to 15minutes on both the sides of the face, stretching exercises of the muscles of the affected side followed by facilitation, specific low intensity exercises to co-ordinate both the halves of the face, active assisted exercises for affected side of the face, exercises of mouth and eye with simultaneous inhibition of synkinesis if present.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the control intervention including the mime therapy
Description: After the baseline assessment, The patient in the experimental group will receive mime therapy Mime therapy include Mime therapy will consists of auto massage- effleurage and kneading for 10 to 15minutes on both the sides of the face, stretching exercises of the muscles of the affected side followed by facilitation, specific low intensity exercises to co-ordinate both the halves of the face, active assisted exercises for affected side of the face, exercises of mouth and eye with simultaneous inhibition of synkinesis if present.
Study: NCT00840853

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD19CAR/virus specific T cells
Description: CD19CAR/virus specific T cells will be thawed and given by intravenous injection from day +30 post transplant.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD19CAR/virus specific T cells
Description: CD19CAR/virus specific T cells will be thawed and given by intravenous injection from day +30 post transplant.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD19CAR/virus specific T cells
Description: CD19CAR/virus specific T cells will be thawed and given by intravenous injection from day +30 post transplant.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD19CAR/virus specific T cells
Description: CD19CAR/virus specific T cells will be thawed and given by intravenous injection from day +30 post transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benadryl and Tylenol
Description: Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benadryl and Tylenol
Description: Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benadryl and Tylenol
Description: Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benadryl and Tylenol
Description: Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.
Study: NCT01087892

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic drink containing the live strain
Description: Probiotic drink contains no strain

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo probiotic
Description: Placebo product is a sweetened flavoured, non fermented, acidified dairy drink
Study: NCT01734304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccination for postremission therapy in AML
Description: Vaccination with TLR7/8-matured DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65
Study: NCT03536806

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Patients assigned to control group will be administered saline 0.9% in bolus of 10 cm3 within 2-3 minutes. BP will be measured before injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canrenone
Description: Patients assigned to canrenone group will be administered canrenone in bolus of 200 mg diluted to 10 cm3 within 2-3 minutes in one dose. Drug administration will be stopped in case of serious adverse event. Further treatment of the patient will depend on clinical condition and will follow appropriate clinical guidelines.
Study: NCT02471196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: ORM-12741 low dose twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: ORM-12741 high dose twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice a day
Study: NCT02846974

Intervention type: DEVICE
Intervention: Pulse oximeter
Description: A pulse oximeter will be used for calibration

Intervention type: DEVICE
Intervention: Pulse oximeter
Description: A pulse oximeter will be used for calibration
Study: NCT03273634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Pill
Description: once daily at night time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01511848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DFP (ferriprox) and deferasirox (ICL 670)
Description: Drug: Ferriprox It will be given orally in the morning Other Name: DFP Initial dose 25/mg/kg 3 times/d (better tolerated if started and then built up over 4 weeks).~Dose may be increased up to 100mg/kg/day guided by serum ferritin. Agranulocytosis risk 1-2%. Monitor TLC and granulocytic count / 2weeks. Patients need to be continually educated about this risk, know that they must stop DFP if they have a fever or infection.~Drug: Deferasirox will be orally administered at a dose of 20 mg/kg once daily at evening for 5 days.~Other Name: ICL670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DFP, DFO
Description: Drug: Deferoxamine It will be administered subcutaneously over 8 hours for 5 days at a dose of 40 mg/kg.~Other Name: Desferal, DFO Drug: DFP DFP: will be orally administered at a dose of 75mg/kg orally in 3 divided doses for 7 days
Study: NCT04395105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose Dexamethasone
Description: IV Dexamethasone administered once daily: 16 mg from day 1 to 5 and 8 mg from day 6 to 10
Study: NCT00862134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR104
Description: 770 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 60 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Description: Subjects randomized to PR104/docetaxel will receive prophylactic G-CSF per package insert administration recommendations. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT02560948

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: 4 x 2 injections over 21 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: 4 x 2 injections over 21 days
Study: NCT00737165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal suicide prevention program
Description: A community intervention of multimodal suicide prevention program includes following components:~1. Building support networks for suicide prevention and mental health promotion in public health system~2. Primary prevention of suicide and suicide related behaviors~3. Secondary prevention of suicide and suicide related behaviors~4. Tertiary prevention; after care for suicide survivors~5. Suicide prevention targeting for people with substance/alcohol- related disorders , schizophrenia and other mental health disorders~6. Suicide prevention targeting for people with work-related problems

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Suicide prevention program as usual
Description: Usual suicide prevention program
Study: NCT00955409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001(10µg) + QS21
Description: Vanutide Cridificar (ACC-001) 10µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001(30µg) + QS21
Description: Vanutide Cridificar (ACC-001) 30 µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
Study: NCT01690858

Intervention type: OTHER
Intervention: blood sample
Description: blood sampling at inclusion and throughout pregnancy when pregnant
Study: NCT01011829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
Study: NCT03169387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: For the VRG training, Microsoft's Xbox 360® will be used with Kinect™, which features an infrared camera sensor that recognizes user movements without a controller. The games used will be YourShape™(Fitness Evolved) and Dance Central 3™, which will be played for 25 minutes each; the former will be associated with the use of Velcro weights on the ankles and dumbbells in the hands to provide resistance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training
Description: treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training, which will be carried out in 3 sets of 10 repetitions, with a recovery interval of 1 minute between sets.
Study: NCT01777854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: The principal investigator will be contacted and will work with the research pharmacist to obtain the omeprazole (20 mg PO daily for patients \>20kg) and placebo. The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look. The medication will be locked in the designated medication cabinet at each office. It will be prepackaged for a 28 day course. The patient will start the treatment 4 weeks prior to tonsillectomy and stop the day before surgery. The medication will be given to the patient once the consent and assent are signed. This will avoid an unnecessary office visit to improve patient compliance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omeprazole
Description: The principal investigator will be contacted and will work with the research pharmacist to obtain the omeprazole (20 mg PO daily for patients \>20kg) and placebo. The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look. The medication will be locked in the designated medication cabinet at each office. It will be prepackaged for a 28 day course. The patient will start the treatment 4 weeks prior to tonsillectomy and stop the day before surgery. The medication will be given to the patient once the consent and assent are signed. This will avoid an unnecessary office visit to improve patient compliance.
Study: NCT03335462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paravertebral injections
Description: Paravertebral injections will be performed in the thoraco-lumbar plexus area under CT guidance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT scan
Description: CT scan will be performed as the needles are kept in their position after injecting the contrast
Study: NCT05029765

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: Mediterranean diet:~22% Monounsaturated fat, 6% Polyunsaturated fat, 7% Saturated fat, 15% Protein, 50% Carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mediterranean diet
Description: Mediterranean diet:~22% Monounsaturated fat, 6% Polyunsaturated fat, 7% Saturated fat, 15% Protein, 50% Carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Healthy diet (WHO recommendations)
Description: Recommendations according to WHO

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Biopolis-MIX42
Description: Biopolis-MIX42: a capsule containing 10\^9 colony forming units of Lactobacillus rhamnosus and Bifidobacterium longum.
Study: NCT01280279

Intervention type: OTHER
Intervention: education for behavioral modification
Description: a systematized 30-minutes education program for behavioral modification (SBMP) by watching videos and discussion with a specialized continence nurse practitioner.
Study: NCT02833610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab Q4W
Study: NCT04528836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-398 (Formerly known as IACS-15509)
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-398 (Formerly known as IACS-15509)
Description: oral capsules
Study: NCT03101748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV